African Trypanosomiasis: Symptoms, Treatments, Medications and Prevention

African trypanosomiasis, commonly known as sleeping sickness, is a parasitic disease caused by Trypanosoma parasites. It is transmitted to humans through the bite of infected tsetse flies, which are found only in sub-Saharan Africa. There are two forms of the disease, depending on the parasite involved: Trypanosoma brucei gambiense causes a chronic form of the disease that predominates in West and Central Africa, while Trypanosoma brucei rhodesiense causes an acute form found primarily in East and Southern Africa.


What is African Trypanosomiasis?

African trypanosomiasis, or sleeping sickness, is a vector-borne parasitic disease caused by Trypanosoma brucei parasites, which are transmitted to humans through the bite of infected tsetse flies (genus Glossina). The disease is characterized by two distinct forms:

  • Gambian sleeping sickness, caused by Trypanosoma brucei gambiense, which progresses more slowly and is chronic.
  • Rhodesian sleeping sickness, caused by Trypanosoma brucei rhodesiense, which progresses rapidly and is acute.

Parasite Lifecycle

Once the tsetse fly bites a human, the Trypanosoma parasites enter the bloodstream, lymphatic system, and eventually the central nervous system. The disease progresses through two stages:

  1. Haemolymphatic Stage: The parasites multiply in the blood and lymphatic system. At this point, the disease can be treated effectively.
  2. Neurological Stage: The parasites cross the blood-brain barrier, invading the central nervous system. This stage is more difficult to treat and leads to severe neurological symptoms, including sleep disturbances, hence the name “sleeping sickness.”

If left untreated, the disease is usually fatal due to neurological complications, systemic organ failure, or secondary infections.


Who is at Risk of African Trypanosomiasis?

African trypanosomiasis is a disease of poverty, primarily affecting people living in rural, remote areas where healthcare access is limited. Various factors influence who is most at risk of contracting the disease.

High-Risk Populations

1. People Living in Endemic Areas

Sleeping sickness is found only in sub-Saharan Africa, where tsetse flies are endemic. People living in rural areas with dense vegetation, riverbanks, and savannahs—areas where tsetse flies thrive—are at higher risk. These populations often lack access to medical care, making diagnosis and treatment challenging.

2. Rural Farmers and Cattle Herders

Tsetse flies tend to be abundant in areas with livestock or game animals, which are the natural reservoirs for the Trypanosoma parasites. Farmers, herders, and others working with cattle or living near wildlife are at higher risk of being bitten by infected tsetse flies.

3. Tourists and Travelers

While the risk to travelers is relatively low, individuals visiting or working in tsetse fly-infested areas, especially those participating in safaris, hunting, or fieldwork in remote locations, are at risk of contracting the disease if preventive measures are not taken.

4. Healthcare Workers in Endemic Areas

Healthcare workers in endemic regions, especially those involved in diagnosis and treatment of sleeping sickness, may be exposed to infected blood or body fluids during medical procedures, although direct person-to-person transmission is rare.

5. People with Poor Access to Healthcare

African trypanosomiasis primarily affects individuals in remote, rural areas where healthcare infrastructure is limited. Without access to early diagnosis and treatment, the disease progresses to its more severe and fatal stages.


Symptoms of African Trypanosomiasis

The symptoms of African trypanosomiasis vary depending on the stage of the infection and the species of Trypanosoma involved. The disease progresses in two stages: the early haemolymphatic stage and the late neurological stage.

Early Symptoms (Haemolymphatic Stage)

During the early stage, the parasites multiply in the bloodstream and lymphatic system. This stage lasts weeks to months for T. b. rhodesiense (acute form) and months to years for T. b. gambiense (chronic form).

1. Chancre (Skin Lesion)

  • A painful sore, known as a trypanosomal chancre, may develop at the site of the tsetse fly bite within 1-3 weeks after infection.
  • The chancre is often mistaken for an insect bite and may heal on its own after a few days.

2. Fever and Fatigue

  • Intermittent fever is one of the first systemic signs of African trypanosomiasis. The fever may be high and recurrent.
  • Fatigue, general malaise, and weakness are common early symptoms.

3. Headaches and Muscle Aches

  • Intense headaches and muscle aches (myalgia) are frequently reported in the early stage of infection.

4. Swollen Lymph Nodes

  • Swelling of lymph nodes, especially in the posterior cervical region (known as Winterbottom’s sign), is characteristic of Gambian sleeping sickness.
  • Enlarged lymph nodes may be tender to the touch.

5. Weight Loss

  • Unexplained weight loss may occur as the disease progresses, even in the absence of significant appetite reduction.

6. Rashes and Skin Irritation

  • Some patients develop itchy skin rashes or generalized skin irritation, particularly in Gambian trypanosomiasis.

Late Symptoms (Neurological Stage)

If left untreated, the disease progresses to the neurological stage, when the parasites cross the blood-brain barrier and infect the central nervous system. This stage is more severe and life-threatening.

1. Sleep Disturbances

  • The hallmark of African trypanosomiasis is disruption of the sleep-wake cycle. Patients may experience excessive daytime sleepiness, insomnia, or irregular sleep patterns, giving rise to the name “sleeping sickness.”
  • In advanced cases, patients may fall asleep suddenly during the day, even while engaged in conversation or activities.

2. Confusion and Cognitive Decline

  • Mental confusion, difficulty concentrating, and cognitive decline are common as the disease progresses.
  • Severe cases may lead to delirium or hallucinations.

3. Neurological Deficits

  • Neurological symptoms, such as tremors, muscle weakness, abnormal movements, and difficulty walking (ataxia), become more pronounced as the infection spreads in the brain.
  • Patients may also experience seizures or paralysis in severe cases.

4. Personality Changes

  • Mood swings, irritability, and behavioral changes are common as the central nervous system becomes increasingly affected.
  • Patients may become apathetic, withdrawn, or aggressive.

5. End-Stage Symptoms

  • In the final stages, untreated African trypanosomiasis leads to severe neurological complications, including coma and death, typically from systemic organ failure or secondary infections.

Diagnosis of African Trypanosomiasis

Diagnosing African trypanosomiasis can be challenging due to its non-specific early symptoms, which may resemble other febrile illnesses common in sub-Saharan Africa, such as malaria or tuberculosis. A combination of clinical evaluation, laboratory tests, and imaging studies is used to confirm the diagnosis.

Clinical Evaluation

The first step in diagnosing African trypanosomiasis is a thorough clinical evaluation. Healthcare providers will inquire about the patient’s symptoms, travel history, and potential exposure to tsetse flies in endemic areas.

1. Physical Examination

During the physical examination, healthcare providers will look for signs such as:

  • Chancre: A sore at the site of the tsetse fly bite.
  • Fever: Persistent or intermittent fever.
  • Winterbottom’s Sign: Enlarged posterior cervical lymph nodes, particularly in Gambian sleeping sickness.
  • Neurological Symptoms: Sleep disturbances, confusion, or motor deficits in advanced cases.

Laboratory Tests for African Trypanosomiasis

Several laboratory tests are available to confirm the diagnosis by detecting the Trypanosoma parasites in blood, lymph, or cerebrospinal fluid (CSF).

1. Microscopic Examination

Microscopic examination of blood, lymph node aspirate, or cerebrospinal fluid is the most commonly used diagnostic method for African trypanosomiasis.

  • Blood Smear: A drop of blood is examined under a microscope to detect the presence of Trypanosoma parasites. This method is particularly effective in the early stages of rhodesiense infection, where parasite levels in the blood are high.
  • Lymph Node Aspirate: In cases of Gambian trypanosomiasis, swollen lymph nodes may be aspirated, and the fluid examined for parasites.
  • Cerebrospinal Fluid Examination: If neurological involvement is suspected, a lumbar puncture is performed to analyze cerebrospinal fluid (CSF) for the presence of parasites and elevated white blood cells, which indicate central nervous system infection.

2. Serological Tests

Serological tests detect antibodies produced by the immune system in response to the Trypanosoma infection. These tests are particularly useful for screening and early detection of Gambian trypanosomiasis.

  • Card Agglutination Test for Trypanosomiasis (CATT): This is a widely used screening test for detecting antibodies against T. b. gambiense. It is simple and rapid, making it useful for mass screening in endemic areas.

3. Polymerase Chain Reaction (PCR)

PCR is a molecular diagnostic technique that detects the DNA of Trypanosoma parasites in clinical samples. PCR is highly sensitive and specific, allowing for early detection, even when parasite levels in the blood are low.

Imaging Studies

In advanced cases with suspected neurological involvement, imaging studies may be used to assess the extent of brain damage.

1. Magnetic Resonance Imaging (MRI)

MRI can help identify structural changes in the brain caused by the disease, particularly in the late neurological stage. However, this imaging technique is not commonly used in resource-limited settings.


Treatments for African Trypanosomiasis

The treatment of African trypanosomiasis varies depending on the stage of the disease and the subspecies of Trypanosoma involved. Early diagnosis and prompt treatment are crucial to prevent the disease from progressing to the neurological stage, where treatment becomes more complicated and less effective.

Treatment of Early-Stage African Trypanosomiasis (Haemolymphatic Stage)

In the early, haemolymphatic stage of the disease, treatment is more straightforward, and the prognosis is generally good if diagnosed and treated promptly.

1. Pentamidine (for T. b. gambiense)

Pentamidine is the first-line treatment for early-stage Gambian sleeping sickness. It is highly effective in clearing the parasite from the blood and lymphatic system.

  • Dosage: Typically administered as an intramuscular or intravenous injection over 7-10 days.
  • Side Effects: Common side effects include nausea, fatigue, and hypotension. Serious side effects, such as kidney damage or heart arrhythmias, are rare but can occur.

2. Suramin (for T. b. rhodesiense)

Suramin is used to treat early-stage Rhodesian sleeping sickness. It is effective in clearing the parasites from the blood and lymphatic system but cannot cross the blood-brain barrier, so it is not effective for the neurological stage.

  • Dosage: Administered as an intravenous infusion over several weeks.
  • Side Effects: Suramin can cause allergic reactions, kidney damage, and nerve damage. Monitoring of renal function is essential during treatment.

Treatment of Late-Stage African Trypanosomiasis (Neurological Stage)

Once the disease progresses to the neurological stage, treatment becomes more complex, as the parasites have crossed the blood-brain barrier. Specialized drugs that can reach the central nervous system are required.

1. Melarsoprol (for Both Forms)

Melarsoprol is the traditional treatment for late-stage African trypanosomiasis. It is highly toxic but remains the only option in many cases of late-stage disease, particularly for T. b. rhodesiense infections.

  • Dosage: Administered as an intravenous injection over 10 days. The drug is usually given in cycles to reduce toxicity.
  • Side Effects: Melarsoprol is associated with severe side effects, including encephalopathy (brain inflammation), which can be fatal in 5-10% of patients. Other side effects include vomiting, abdominal pain, and peripheral neuropathy.

2. Eflornithine (for T. b. gambiense)

Eflornithine is used to treat late-stage Gambian sleeping sickness. It is less toxic than melarsoprol and is more effective in crossing the blood-brain barrier.

  • Dosage: Administered intravenously over 14 days, often in combination with nifurtimox (NECT protocol).
  • Side Effects: Common side effects include diarrhea, bone marrow suppression, and electrolyte imbalances.

3. Nifurtimox-Eflornithine Combination Therapy (NECT)

NECT is the first-line treatment for late-stage Gambian sleeping sickness. This combination therapy reduces the duration and toxicity of eflornithine monotherapy.

  • Dosage: Eflornithine is given intravenously, while nifurtimox is taken orally.
  • Side Effects: NECT is better tolerated than melarsoprol but can still cause gastrointestinal symptoms, bone marrow suppression, and neurological effects.

Follow-Up Care

After treatment, patients must be monitored for relapse or treatment failure. Follow-up care typically includes:

  • Clinical Evaluation: Patients should be re-evaluated periodically to assess for signs of relapse.
  • Cerebrospinal Fluid Examination: In cases of late-stage disease, repeat lumbar punctures may be needed to confirm that the parasites have been eradicated from the central nervous system.

Common Medications for African Trypanosomiasis

Several medications are commonly used to treat African trypanosomiasis, depending on the stage of the disease and the specific subspecies involved. The most frequently prescribed medications include:

1. Pentamidine

Pentamidine is the first-line treatment for early-stage Gambian sleeping sickness. It is highly effective and has a relatively good safety profile compared to other drugs used for African trypanosomiasis.

  • How It Works: Pentamidine interferes with the parasite’s DNA and RNA synthesis, leading to cell death.
  • Side Effects: Common side effects include hypotension, nausea, and kidney dysfunction. Serious side effects, such as liver toxicity or cardiovascular problems, are rare.

2. Suramin

Suramin is used to treat early-stage Rhodesian sleeping sickness. It is highly effective in clearing the parasites from the blood and lymphatic system but cannot cross the blood-brain barrier.

  • How It Works: Suramin inhibits enzymes essential for the survival of Trypanosoma parasites, leading to their death.
  • Side Effects: Suramin can cause allergic reactions, kidney toxicity, and nerve damage. Careful monitoring is required during treatment.

3. Melarsoprol

Melarsoprol is used to treat late-stage African trypanosomiasis, especially in T. b. rhodesiense infections. Despite its high toxicity, it is often the only option for advanced-stage disease.

  • How It Works: Melarsoprol is an arsenic-based compound that disrupts the parasite’s metabolism and leads to cell death.
  • Side Effects: The most severe side effect is encephalopathy, which can be fatal. Other side effects include abdominal pain, vomiting, and peripheral neuropathy.

4. Eflornithine

Eflornithine is the preferred treatment for late-stage Gambian sleeping sickness due to its better safety profile compared to melarsoprol.

  • How It Works: Eflornithine inhibits ornithine decarboxylase, an enzyme essential for parasite growth, leading to parasite death.
  • Side Effects: Common side effects include gastrointestinal upset, bone marrow suppression, and electrolyte imbalances.

5. Nifurtimox

Nifurtimox is used in combination with eflornithine (NECT protocol) for the treatment of late-stage Gambian sleeping sickness. It enhances the effectiveness of eflornithine while reducing the duration of treatment.

  • How It Works: Nifurtimox generates free radicals that damage the parasite’s DNA and proteins, leading to cell death.
  • Side Effects: Nifurtimox can cause gastrointestinal symptoms, neurological disturbances, and hypersensitivity reactions.

Where is African Trypanosomiasis Most Prevalent?

African trypanosomiasis is endemic to sub-Saharan Africa, where the tsetse fly is native. The disease affects 36 countries in the region, though its distribution varies between the two forms of sleeping sickness.

Geographic Distribution

1. West and Central Africa (Gambian Sleeping Sickness)

Gambian sleeping sickness, caused by T. b. gambiense, is the most common form of African trypanosomiasis and accounts for over 95% of reported cases. It is found in West and Central Africa, where transmission occurs primarily in rural areas with dense vegetation, rivers, and swamps.

Countries with the highest prevalence of Gambian sleeping sickness include:

  • Democratic Republic of the Congo: Over 70% of cases are reported from the DRC, making it the epicenter of the disease.
  • Angola
  • South Sudan
  • Central African Republic
  • Chad
  • Guinea

2. East and Southern Africa (Rhodesian Sleeping Sickness)

Rhodesian sleeping sickness, caused by T. b. rhodesiense, is less common but more acute and severe than the Gambian form. It occurs in East and Southern Africa, primarily in areas with game reserves, savannahs, and cattle herding.

Countries with significant cases of Rhodesian sleeping sickness include:

  • Uganda: The only country where both forms of the disease are found, with the northern part affected by Gambian sleeping sickness and the southern part affected by Rhodesian sleeping sickness.
  • Tanzania
  • Malawi
  • Zambia
  • Zimbabwe

3. Decline in Cases

Due to sustained efforts in surveillance, treatment, and vector control, the number of reported cases of African trypanosomiasis has significantly decreased over the past few decades. The World Health Organization (WHO) has set a goal to eliminate Gambian sleeping sickness as a public health problem by 2030.


Prevention of African Trypanosomiasis

Preventing African trypanosomiasis involves a combination of strategies to reduce tsetse fly populations, avoid bites, and implement active surveillance and early treatment in endemic regions. While there is no vaccine available, several measures can help reduce the risk of contracting the disease.

Vector Control

Controlling the population of tsetse flies is one of the most effective strategies for reducing the incidence of African trypanosomiasis.

1. Insecticide-Treated Targets

Insecticide-treated targets, such as blue or black cloths soaked in insecticide, attract and kill tsetse flies. These targets can be placed in areas where tsetse flies are common, such as near rivers, forests, and grazing areas.

2. Sterile Insect Technique (SIT)

The sterile insect technique involves releasing sterilized male tsetse flies into the environment. These males mate with females, but no offspring are produced, gradually reducing the tsetse fly population over time.

3. Aerial Spraying

In some regions, aerial spraying of insecticides is used to control large populations of tsetse flies. This method is effective but can be costly and has potential environmental impacts.

Personal Protection Measures

Individuals living or traveling in tsetse fly-endemic areas can reduce their risk of infection by taking precautions to avoid being bitten.

1. Wearing Protective Clothing

Tsetse flies are attracted to bright and dark colors, especially blue and black. Wearing neutral-colored, long-sleeved clothing that covers as much skin as possible can help reduce the risk of being bitten. Tsetse flies can bite through light clothing, so wearing thicker fabrics is recommended.

2. Using Insect Repellents

While tsetse flies are not as easily repelled as mosquitoes, using insect repellents containing DEET or other effective compounds can offer some protection.

3. Avoiding Tsetse Fly Habitats

Avoiding areas where tsetse flies are known to be abundant, such as dense vegetation, riverbanks, and game parks, can reduce the risk of exposure. Tsetse flies are most active during the day, so avoiding outdoor activities in tsetse fly-infested areas during peak times is advisable.

Early Diagnosis and Treatment

Early diagnosis and prompt treatment are essential for preventing the spread of African trypanosomiasis and reducing mortality rates.

1. Active Surveillance

Active surveillance programs in endemic regions are crucial for detecting new cases of African trypanosomiasis. Mobile teams can visit remote villages to screen people for the disease using serological tests (CATT) or other diagnostic methods. Early detection allows for timely treatment, reducing the risk of severe complications or death.

2. Mass Screening and Treatment

Mass screening campaigns can help identify infected individuals, particularly in high-risk areas where many people may be asymptomatic. Treating those who test positive reduces the reservoir of infection in the community, helping to break the transmission cycle.

Public Health Education

Raising awareness about African trypanosomiasis and its prevention is essential for controlling the disease in endemic regions.

1. Community Education Programs

Community-based education programs can teach people about the risks of sleeping sickness, how to recognize early symptoms, and the importance of seeking medical treatment. These programs can also inform communities about protective measures, such as using insecticide-treated clothing and avoiding tsetse fly habitats.

2. Training Healthcare Workers

Healthcare workers in endemic regions should be trained to recognize the early signs of African trypanosomiasis and provide timely treatment. Improving the capacity of local health systems to diagnose and treat the disease is critical for reducing its burden.

You may also like...